Neurocrine Biosciences has reported positive results from pooled analyses of the long-term effects of Ingrezza (valbenazine) in decreasing abnormal movements in tardive dyskinesia (TD) disorder.
TD is characterised by persistent involuntary movements of the face, torso and/or other body parts.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor intended to minimise the amount of dopamine in a brain region that regulates movement and motor function.
It has US Food and Drug Administration (FDA) approval to treat adults suffering from TD.
Pooled analyses from the Phase III KINECT 3 and KINECT 4 trials showed that a once-daily 40mg dose of the drug led to a response on the Abnormal Involuntary Movement Scale (AIMS) scale in 53.7% of patients treated for 48 weeks.
Ingrezza also demonstrated a Clinical Global Impression of Change-Tardive Dyskinesia (CGI-TD) response in 65.5% of patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition, data from the Phase III KINECT 3 trial revealed early response following two weeks of therapy with a 40mg or 80mg dose in 50% of participants.
Irrespective of the response at two weeks, meaningful reductions in the disorder were observed with long-term treatment.
According to the data, the drug was generally well-tolerated without any new safety concerns or notable worsening of psychiatric symptoms.
Neurocrine Biosciences chief medical officer Eiry Roberts said: “The analyses of pooled data continue to support the growing body of evidence that Ingrezza is an effective treatment for the long-term management of tardive dyskinesia.
“It is important to choose the best dosing option of Ingrezza and continue treatment to achieve long-term outcomes as tardive dyskinesia varies from patient to patient as well as their treatment response.”
The Phase III KINECT 3 and KINECT 4 studies were conducted in 234 and 163 moderate to severe TD patients, respectively.
